FDA OKs ViiV Healthcare’s two-drug HIV combo

The FDA approves Viiv Healthcare’s Dovato (dolutegravir and lamivudine) for the treatment of HIV-1 infection in adults who have not received prior antiretroviral treatment, the first fixed-dose two-drug combo regimen available in the U.S. for these patients.

ViiV Healthcare is the HIV-focused joint venture between GlaxoSmithKline (GSK +0.2%), Pfizer (PFE +0.2%) and Shionogi (OTCPK:SGIOY -0.4%).

https://seekingalpha.com/news/3449110-fda-oks-viiv-healthcares-two-drug-hiv-combo